Report cover image

Dyspepsia Drugs Market - Indication (Functional, Organic), Drug Type (Proton Pump Inhibitors, H-2-Receptor Antagonists, Antacids, Antibiotics), Medication (Branded, Generic), Mode (OTC, Prescription), Distribution Channel, Global Forecast (2024-2032)

Publisher Global Market Insights
Published Dec 13, 2023
Length 180 Pages
SKU # GMI19897465

Description

Dyspepsia Drugs Market - Indication (Functional, Organic), Drug Type (Proton Pump Inhibitors, H-2-Receptor Antagonists, Antacids, Antibiotics), Medication (Branded, Generic), Mode (OTC, Prescription), Distribution Channel, Global Forecast (2024-2032)


Dyspepsia Drugs Market is expected to witness 4.5% CAGR from 2024 to 2032 owing to the escalating incidence of digestive disorders across demographics. The modern lifestyle, characterized by erratic eating habits, increased stress levels, and sedentary behavior, has contributed to a surge in digestive issues, leading to a growing demand for dyspepsia medications.

According to the National Hospital Ambulatory Medical Care Survey 2021, nearly 8.4 million people visited emergency departments for digestive system issues. The aging population is more susceptible to gastrointestinal problems, creating a sustained need for advanced and efficient dyspepsia drugs. As healthcare awareness increases, patients seek prompt and effective solutions, further stimulating the market growth.

The dyspepsia drugs market is classified based on indication, drug type, medication, mode, distribution channel, and region.

The organic indication segment is anticipated to record 4% CAGR between 2024 and 2032. Consumers are increasingly seeking natural and holistic approaches to manage digestive discomfort, driving the demand for organic dyspepsia medications. This shift towards organic solutions aligns with the broader trend of health-conscious consumer choices. As a result, pharmaceutical companies are investing in R&D to create innovative organic dyspepsia drugs, offering a comprehensive range of treatment options to meet the evolving preferences of consumers.

The generic medication segment will observe more than 5.8% CAGR during 2024 and 2032 as they are affordable alternatives provided to a broader patient base. With the expiration of patents for several branded dyspepsia drugs, generic versions have become prevalent, offering cost-effective solutions without compromising efficacy. This has not only improved accessibility but has also intensified the competition, fostering innovation and driving down overall treatment costs. As healthcare systems worldwide strive for cost containment, the generic medication segment will record notable growth.

Europe dyspepsia drugs market size is predicted to observe 3.8% CAGR over the forecast, driven by the increasing prevalence of digestive disorders and a proactive healthcare infrastructure. European population is experiencing a surge in gastrointestinal issues due to dietary changes, lifestyle factors, and aging. The commitment to healthcare innovation and research is resulting in the development of advanced dyspepsia drugs. Moreover, stringent regulatory standards ensure the safety and efficacy of these medications, fostering confidence among both healthcare providers and patients.

Table of Contents

180 Pages
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Data validation
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Public sources
Chapter 2 Executive Summary
2.1 Dyspepsia drugs industry 360 degree synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Indication trends
2.1.4 Drug type trends
2.1.5 Medication trends
2.1.6 Mode trends
2.1.7 Distribution channel trends
Chapter 3 Dyspepsia Drugs Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of dyspepsia
3.2.1.2 Growing aging population
3.2.1.3 Rising preference for over-the-counter (OTC) medications
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with the dyspepsia drugs
3.2.2.2 Availability of alternative therapies
3.3 Growth potential analysis
3.3.1 By indication
3.3.2 By drug type
3.3.3 By medication
3.3.4 By mode
3.3.5 By distribution channel
3.4 Regulatory landscape
3.5 Pricing analysis
3.6 Epidemiology
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis, 2023
4.3 Competitive analysis of major market players, 2023
4.4 Competitive positioning matrix, 2023
4.5 Strategic dashboard, 2023
Chapter 5 Dyspepsia Drugs Market Estimates and Forecast, By Indication, 2018-2032 (USD Million)
5.1 Key trends, by indication
5.2 Functional dyspepsia
5.3 Organic dyspepsia
Chapter 6 Dyspepsia Drugs Market Estimates and Forecast, By Drug Type, 2018-2032 (USD Million)
6.1 Key trends, by drug type
6.2 Proton pump inhibitors
6.3 H-2-receptor antagonists
6.4 Antacids
6.5 Antibiotics
6.6 Prokinetics
6.7 Antidepressants
Chapter 7 Dyspepsia Drugs Market Estimates and Forecast, By Medication, 2018-2032 (USD Million)
7.1 Key trends, by medication
7.2 Branded
7.3 Generic
Chapter 8 Dyspepsia Drugs Market Estimates and Forecast, By Mode, 2018-2032 (USD Million)
8.1 Key trends, by mode
8.2 Over-the-counter
8.3 Prescription
Chapter 9 Dyspepsia Drugs Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Million)
9.1 Key trends, by distribution channel
9.2 Retail pharmacies
9.3 Hospital pharmacies
9.4 Online pharmacies
Chapter 10 Dyspepsia Drugs Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East & Africa
Chapter 11 Company Profiles
11.1 Takeda Pharmaceutical Company Limited
11.2 AstraZeneca plc
11.3 Salix Pharmaceuticals, Inc.
11.4 Abbott Laboratories
11.5 Pfizer Inc.
11.6 Sanofi SA
11.7 Procter & Gamble
11.8 Haleon plc
11.9 ANI Pharmaceuticals, Inc.
11.10 Dr Reddy’s Laboratories Ltd.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us